» Articles » PMID: 12702151

Identification of Genes Down-regulated During Melanoma Progression: a CDNA Array Study

Overview
Journal Exp Dermatol
Specialty Dermatology
Date 2003 Apr 19
PMID 12702151
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

In order to identify genes relevant for melanoma development, we carried out cDNA array experiments employing an in vitro model of human melanoma progression, consisting of two cell lines: one, LP, derived from a primary melanoma and the other, LM, from its metastatic supraclavicular lymph node. Basic cDNA array data identified 26 genes as down-regulated in the LM cell line. Northern blot analysis confirmed an effective transcriptional down-regulation for five out of 13 genes analyzed. The products of these five genes belong to different functional protein types, such as transcription and translation regulators (Edg-2, eIF-3 p110, and RNPL/RBM3), extracellular communicators (PRSS11) and members of the major histocompatibility complex (beta2-microglobulin). Some previously described differences in expression patterns, such as loss of HLA I, were confirmed by our array data. In addition, we identified and validated for the first time the reduced expression level of several genes during melanoma progression. In particular, reduced Edg-2 gene product expression was also confirmed in a group of 50 primary melanomas and unrelated metastases. In conclusion, comparative hybridization by means of cDNA arrays assisted in identifying a series of novel progression-associated changes in gene expression, confirming, at the same time, a number of previously described results.

Citing Articles

Translation regulation in skin cancer from a tRNA point of view.

Grafanaki K, Anastasakis D, Kyriakopoulos G, Skeparnias I, Georgiou S, Stathopoulos C Epigenomics. 2018; 11(2):215-245.

PMID: 30565492 PMC: 6391632. DOI: 10.2217/epi-2018-0176.


Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome.

Grupp K, Hofmann B, Kutup A, Bachmann K, Bogoevski D, Melling N BMC Cancer. 2018; 18(1):1106.

PMID: 30419865 PMC: 6233549. DOI: 10.1186/s12885-018-5032-z.


Cold-inducible proteins CIRP and RBM3, a unique couple with activities far beyond the cold.

Zhu X, Buhrer C, Wellmann S Cell Mol Life Sci. 2016; 73(20):3839-59.

PMID: 27147467 PMC: 5021741. DOI: 10.1007/s00018-016-2253-7.


HtrA1: Its future potential as a novel biomarker for cancer.

Altobelli E, Marzioni D, Lattanzi A, Angeletti P Oncol Rep. 2015; 34(2):555-66.

PMID: 26035313 PMC: 4487665. DOI: 10.3892/or.2015.4016.


High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.

Nodin B, Fridberg M, Jonsson L, Bergman J, Uhlen M, Jirstrom K Diagn Pathol. 2012; 7:82.

PMID: 22805320 PMC: 3433373. DOI: 10.1186/1746-1596-7-82.